For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Cue Biopharma Inc’s stock clocked out at $0.79, up 8.67% from its previous closing price of $0.72. In other words, the price has increased by $8.67 from its previous closing price. On the day, 0.78 million shares were traded.
Ratios:
To gain a deeper understanding of CUE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.03. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 13, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On November 21, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 21, 2022, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’24 when PASSERI DANIEL R bought 30,000 shares for $1.03 per share. The transaction valued at 30,900 led to the insider holds 164,578 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.41 while its Price-to-Book (P/B) ratio in mrq is 7.38.
Stock Price History:
Over the past 52 weeks, CUE has reached a high of $1.99, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is 10.76%, while the 200-Day Moving Average is calculated to be -23.65%.
Shares Statistics:
A total of 75.35M shares are outstanding, with a floating share count of 74.78M. Insiders hold about 0.75% of the company’s shares, while institutions hold 16.46% stake in the company.
